Safety Study Using Weekly Infusions of BB-10901 in Patients With Small Cell Lung Cancer

Status:
Completed

Trial end date:
2008-12-01

Target enrollment:

Participant gender:

This study was a Phase I/II trial primarily focused on efficacy of BB-10901 in relapsed small cell lung cancer and other solid tumors.

Phase 1/Phase 2

ImmunoGen, Inc.

Lorvotuzumab mertansine